• Amarin Corporation PLC AMRN.OQ reported a quarterly adjusted loss of 4 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of three analysts for the quarter was for a loss of 57 cents per share. Wall Street expected results to range from -74 cents to -40 cents per share.

• Revenue fell 25.7% to $42.02 million from a year ago; analysts expected $50.75 million.

• Amarin Corporation PLC's reported EPS for the quarter was a loss of 4 cents​.

• The company reported a quarterly loss of $15.7 million.

• Amarin Corporation PLC shares had risen by 13.7% this quarter and gained 5.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 48.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "sell"

• Wall Street's median 12-month price target for Amarin Corporation PLC is $13.50

This summary was machine generated from LSEG data May 7 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)